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Abstract 19 
The continuous glucose monitoring system (CGMS) allows generation of detailed glucose 20 
curves via measurement of glucose concentration in interstitial fluid. The conventional site for 21 
sensor placement in diabetic cats is the subcutaneous tissue of the lateral chest wall. The aim 22 
of this study was to investigate the feasibility and accuracy of sensors placed in the lateral 23 
chest wall and in two alternative sites, the dorsal neck and lateral knee fold, of diabetic cats. 24 
Initialisation was successful in 15 of 20 lateral chest wall sensors, 9 of 10 neck sensors and 3 25 
of 10 knee fold sensors. Compared with the reference portable blood glucose meter, 0.8% of 26 
measurements from lateral chest wall sensors, 0.7 % from knee fold sensors and 0% from 27 
neck sensors would have resulted in erroneous treatment. 28 
Placement of sensors in the dorsal neck region resulted in improved reliability of CGMS and 29 
made this position preferable for clinical use. 30 
 3  
Introduction 31 
A continuous glucose monitoring system (CGMS) has recently been introduced into 32 
veterinary medicine (1-4). This system measures glucose concentrations in the subcutaneous 33 
interstitial fluid every 5 minutes for up to 72 hours via a glucose-oxidase containing sensor. 34 
The technique provides a potentially less stressful alternative to blood glucose measurements 35 
and generates detailed glucose curves. A good correlation between interstitial fluid and blood 36 
glucose concentrations was shown with the first generation of CGMSs in cats and dogs (1-4). 37 
However, these older systems necessitate attachment of the monitor to the animal and manual 38 
downloading of the recorded data to a computer for analysis. The Guardian REAL-Time
® a
 is 39 
a new generation CGMS that enables on-screen date recording over a 72-hour period. This 40 
system has recently been validated for use in cats and provides clinically accurate and 41 
reproducible measurements in the euglycaemic and hyperglycaemic ranges, but slightly less 42 
accurate results in the hypoglycaemic range (5). 43 
The manufacturer of the Guardian REAL-Time
®
 recommends placing the sensor in an area 44 
with sufficient subcutaneous tissue. In humans, the most suitable sensor site is the abdominal 45 
para-umbilical region. However, a study based on glucose monitoring with microdialysis 46 
showed that readings of abdominal sensors were 20% lower than reference blood glucose 47 
concentrations or readings from sensors placed in the forearm (6). In another study, clinical 48 
accuracy of measurements made using glucose-oxidase containing sensors or the 49 
microdialysis technique in the subcutaneous tissue of the shoulder was higher than in the 50 
upper leg (19). Thus, the recorded values may differ depending on the site of sensor 51 
placement. There are no specific recommendations for sensor placement in cats. In most 52 
studies, the thoracic region has been used (3,17,18). We hypothesize, that the position of the 53 
sensor interferes with its function in cats. The purpose of this study was to determine which 54 
sensor site in the subcutaneous tissue of diabetic cats is more practical and provide most 55 
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accurate results. For comparison the dorsal neck, the knee fold region and the lateral chest 56 
wall were evaluated.  57 
 5  
Materials and Methods 58 
Animals 59 
The study was approved by the Cantonal Veterinary Office of Zurich and conducted in 60 
accordance with guidelines established by the Animal Welfare Act of Switzerland 61 
(permission no.: 83/2008). Informed consent to participate in the study was provided by the 62 
owners. 63 
Eighteen client-owned diabetic cats were used in the study and were hospitalised in the Clinic 64 
for Small Animal Internal Medicine in Zurich. Sixteen had been recently diagnosed with 65 
diabetes mellitus, one had been treated with porcine lente insulin (Caninsulin
®
) for 1 and one 66 
other for 3 years before recruitment. The median age of the cats was 11.0 years (range: 7-21), 67 
median body weight was 5.0 kg (range: 2.5-9.6) and median body condition score
b
 was 5.5 68 
(range: 2-9).Ten cats (55%) were neutered males and eight (44%) were spayed females. There 69 
were 17 (94%) domestic shorthair and one Birman cat. 70 
 71 
Continuous glucose monitoring system 72 
The Guardian REAL-Time
® a
 system for continuous glucose monitoring consists of a 73 
disposable glucose sensor, a transmitter and a recording monitor. The sensor is a flexible 74 
glucose electrode coated with the enzyme glucose oxidase. Glucose in the interstitial fluid 75 
undergoes the following electrochemical reaction: glucose + oxygen   gluconic acid + 76 
H2O2. The produced peroxide dissociates to 2H
+
, oxygen and 2e
-
. This reaction generates a 77 
small electric current which is proportional to glucose concentration in the sensor 78 
environment and is referred to as Input Signal for Glucose (ISIG). The rechargeable 79 
transmitter connects directly to the glucose sensor and wirelessly sends ISIG data to the 80 
monitor, which can be up to 1.8 meter away. The ISIG is subsequently converted to the 81 
prevailing glucose concentration (mmol/l). The ISIG can be read on the monitor in addition to 82 
the glucose value. The function of the monitor is to acquire, display and store signals from the 83 
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subcutaneous glucose sensor. The glucose sensor signal is acquired every 10 seconds. The 84 
monitor stores the data and displays an average of the acquired signals every 5 minutes in 85 
real-time for up to 24 hours. The Guardian REAL-Time monitor is not equipped with a signal 86 
indicator. But the monitor includes a programmable „weak signal“ alert that notifies when one 87 
or more expected transmissions are not received, as expected by the receiving device. The 88 
sensor can be left in place for up to 72 hours. Glucose values can be downloaded onto a 89 
computer for analysis. The monitor has the capability to record glucose concentrations for up 90 
to one month before downloading.  91 
 92 
Experimental design 93 
For comparison of different sensor sites, two glucose sensors were placed one in the 94 
subcutaneous tissue of the lateral chest wall (standard sensor site) and the other in the 95 
subcutaneous tissue of the knee fold or dorsal neck area (alternative sensor sites). Sensors 96 
were placed in the lateral chest wall and dorsal neck region of ten cats and in the lateral chest 97 
wall and knee fold of ten other cats; in two cats both alternative sites were evaluated 98 
consecutively. After clipping and disinfecting the insertion site, the glucose sensor was placed 99 
in the subcutaneous tissue and secured to the skin with cyanoacrylate adhesive
c
. The 100 
transmitter was connected to the sensor and secured in place using a 2.0 ×5.0-cm piece of 101 
tape. The first CGMS calibration was carried out according to the manufacturer’s 102 
recommendation after a 2-hour period of initialisation, during which time glucose 103 
measurements were not made. Thereafter, the CGMS was calibrated after 6 hours and then 104 
every 10 hours. Calibrations were achieved by measuring the glucose concentration of 105 
capillary blood from the inner pinna with the AlphaTRAK
 d
 portable blood glucose meter 106 
(PBGM), which was used as a reference (7,13). Based on previous papers published by our 107 
group (8,9,12) capillary glucose monitoring performed with the portable glucose meter is not 108 
stressful. Sampling of capillary blood using the Microlet Vaculance 
® e 
 device was tolerated 109 
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very well in all cats. The lancing device 
e
 enables an easy and fast capillary blood sampling 110 
(10-13). All veterinarians taking care of the cats during the study were well trained in 111 
sampling capillary blood. Due to intrinsic technical limits of the Guardian REAL-Time
® a
 112 
system only glucose concentrations between 2.2 and 22.2 mmol/l can be used for calibration. 113 
The CGMS, as it is so far marketed, is able to display glucose concentrations between 2.2 and 114 
22.2 mmol/l. However, concentrations beyond this range are  correctly recorded by the 115 
CGMS but need to be downloaded to be analyzed. During our study however, calibration was 116 
postponed until glucose concentration was within the working range. If calibration failed, 15 117 
minutes after entering the glucose value the CGMS monitor displayed “calibration error”. 118 
Based on the CGMS instructions provided by the manufacturer, sources of error can be one of 119 
the following. An incorrect blood glucose measurement was entered from the meter into the 120 
monitor, the blood glucose is rising or falling rapidly, the sensor needs more time to stabilize 121 
after being inserted or the sensor is no longer reading the sensor glucose correctly. 122 
Unfortunately, the CGMS displays “calibration error” but does not indicate the cause of 123 
failure. The CGMS manufacturer recommends waiting for 10-15 minutes after a “calibration 124 
error” is displayed, then to start with a new calibration. If glucose values are increasing or 125 
decreasing very fast, the manufacturer suggests to wait longer (i.e, 15-20 minutes) or to wait 126 
until glucose values are stable. In the present study the suggested recommendations were 127 
followed. When calibration failed, recalibration was attempted after 10 minutes and thereafter 128 
every 30 minutes. Sensors were evaluated for up to 72 hours. 129 
 130 
Analysis 131 
To identify the most practical and reliable site for placing the CGMS sensor in cats, the 132 
following items were analysed: 133 
 134 
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1) Sensor loosening 135 
Detachment of the sensor from the skin on its own or by the cat was recorded for each site. 136 
 137 
2) First sensor calibrations 138 
The proportion of successful first calibrations was calculated for each site. First calibrations 139 
were considered successful when the CGMS was able to display glucose levels recorded by 140 
the sensor, 2 hours after the initialization period. Due to technical limits only calibrations with 141 
capillary blood glucose measurements between 2.2 and 22.2 mmol/l were used. 142 
  143 
3) Sensor recording 144 
For each sensor site the proportion of continuous recordings that lasted at least 48 hours was 145 
calculated. Interruptions of recording shorter than 3 hours were arbitrarily tolerated. In the 146 
authors experience interruptions not longer than 3 hours over a period of 2 or more days, in a 147 
clinical setting, do not affect interpretation of the curves, if the cat has stable glucose levels 148 
and shows no signs of hypoglycaemia (e.g. restlessness, shivering). 149 
 150 
4) Analytical and clinical accuracy 151 
To evaluate accuracy of the CGMS, the glucose concentration of interstitial fluid at the 152 
different sensor sites was compared with capillary blood glucose concentrations measured 153 
with a PBGM every 4 to 6 hours (reference method). Analytical accuracy was calculated by 154 
plotting differences between results of the CGMS and PBGM using Bland and Altmann plots 155 
(14). Clinical accuracy was calculated using the Clarke error grid analysis (15). The grid 156 
system assigns CGMS measured values (y-axis) versus actual glucose values (reference 157 
PBGM, x-axis) to 5 zones (A through E) and is based on the assumption that the clinical goal 158 
is to maintain blood glucose concentrations between 3.9 and 10 mmol/l. Measurements in 159 
zones A and B are clinically accurate and lead to clinically correct treatment decisions. The 160 
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CGMS readings in zone A deviate from the reference value by no more than 20%, or both are 161 
< 3.9 mmol/l. The CGMS readings in zone B represent benign errors and deviate from 162 
reference values by > 20%; however, they do not lead to a change in treatment, or treatment 163 
will not have any harmful effects. Values in zones C, D, and E lead to treatment errors or 164 
failure to initiate treatment. Values in zone C lead to unnecessary correction or overcorrection 165 
of the acceptable glucose concentration and cause the actual blood glucose concentration to 166 
fall below 3.9 mmol/l or to increase above 10 mmol/l. Zone D represents potentially 167 
dangerous errors of failing to detect and treat actual glucose values that are outside the target 168 
range, because CGMS readings are within the target range. The CGMS readings in zone E are 169 
opposite to the actual glucose values, and therapeutic actions would be opposite to those 170 
indicated. 171 
Concordance between measurements of sensors and the reference method was determined by 172 
calculating the proportion of paired readings that were both in the normal (5-10 mmol/l), high 173 
(> 10 mmol/l) and low (< 5 mmol/l) glucose ranges (18). However, because paired readings 174 
may be very close, yet assigned to different glycaemic ranges (e.g. 4.9 versus 5.1 mmol/l), 175 
thus generating disagreement that does not have clinical relevance, we included an additional 176 
arbitrary criterion to evaluate concordance; paired samples considered not to be concordant 177 
required a difference of at least 10%, in addition to being assigned to different glycaemic 178 
ranges. 179 
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Results 180 
Feasibility of the 3 sensor sites 181 
Placement of the sensor and transmitter and visualisation of the data in real-time on the 182 
monitor were successful and straightforward in all cats. The sensor and transmitter were well 183 
tolerated by all cats and adverse skin reactions were not observed at any of the sensor sites.  184 
Successful first calibrations two hours after sensor placement were achieved in 15 of 20 185 
(75%) sensors placed in the lateral chest wall, in 9 of 10 (90%) sensors placed in the neck 186 
region and in 3 of 10 (30%) sensors in the area of the knee fold.   187 
Uninterrupted glucose concentration recordings over a 48-hour period occurred in 17 of 20 188 
(85%) of the sensors that were inserted in the lateral chest wall, and in 7 of 10 (70%) of the 189 
sensors that were inserted in the dorsal neck region and knee fold. Three of 20 (15%) lateral 190 
chest wall sensors, 3 of 10 (30%) dorsal neck sensors and 3 of 10 (30%) knee fold sensors 191 
provided uninterrupted recordings for periods shorter than 48 hours. In all cases 192 
discontinuation of recordings occurred due to calibration errors. Two sensors (1 in the lateral 193 
chest wall and 1 in the knee fold) never recorded glucose values because successful 194 
calibrations were not achieved. Macroscopically the sensors were not deformed, broken or 195 
clogged by proteins or blood; no obvious sensor abnormalities were detected. One sensor in 196 
the dorsal neck region functioned for only 4 hours. Two sensors each in the lateral chest wall, 197 
dorsal neck region and knee fold recorded glucose values for 15 to 38 hours. The remaining 198 
31 sensors provided glucose values for at least 48 hours. 199 
Sensors lost the proper placement under the skin in 1 of 20 (5%) sensors in the lateral chest 200 
wall, 2 of 10 (20%) sensors in the dorsal neck region and 2 of 10 (20%) sensors in the knee 201 
fold. 202 
 203 
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Analytical and clinical accuracy of the 3 sensor sites 204 
491 paired samples were taken to compare glucose concentrations measured with the CGMS 205 
against the reference PBGM. Differences between glucose concentrations measured with the 206 
CGMS and PBGM are shown in Bland and Altmann plots (Figure 1). The mean  2-standard 207 
deviations (2SD) of the difference was 0.96 ± 6.76 mmol/l in the lateral chest wall, 0.60  208 
5.24 mmol/l in the dorsal neck and 0.62  5.24 mmol/l in the knee fold region. The maximum 209 
deviation for sensors in the lateral chest wall was 18 mmol/l, in the dorsal neck region 7.9 210 
mmol/l and in the knee fold area 14.8 mmol/l. 211 
Results of the Clarke error grid analysis are shown in Figure 2. Overall, 472 of the 491 212 
(96.1%) paired glucose measurements were in zones A or B; this included 94.3% of glucose 213 
measurements from sensors in the lateral chest wall, 96.7% from the dorsal neck region and 214 
99.3% from the knee fold. There were no measurements in zone C. Of the measurements from 215 
the lateral chest wall, 4.9% were in zone D and 0.8% in zone E, from the dorsal neck, 3.3% 216 
were in zone D and from the knee fold, 0.7% were in zone E. 217 
There was concordance between values generated by the CGMS and PBGM in 78.3% of 218 
measurements from sensors in the lateral chest wall, in 80.0% of measurements from sensors 219 
in the neck area and in 76.5% of measurements from sensors in the knee fold. 220 
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Discussion 221 
This study investigated the feasibility and accuracy of CGMS sensors placed at different sites 222 
of the body in diabetic cats. Sensor placement in the subcutaneous tissue of the lateral chest 223 
wall, dorsal neck region and knee fold was quick and easy and did not yield apparent 224 
discomfort. Sensors in all three sites were well tolerated, and adverse skin reactions at the 225 
place of insertion were not observed after sensor removal. Overall, CGMS sensors placed in 226 
the dorsal neck region worked better than those placed in the lateral chest wall or knee fold. 227 
Following the initialisation period, successful first calibrations were achieved with 90% of 228 
sensors placed in the dorsal neck and 75% of sensors in the lateral chest wall, but with only 229 
30% of sensors placed in the knee fold. The high proportion of unsuccessful first calibrations 230 
in the knee fold may have been attributable to poor capillary vascularisation in that region and 231 
thus insufficient contact between the sensor and interstitial fluid. Studies in humans and dogs 232 
suggest that the subcutaneous tissue in this area has less than optimal capillary blood supply 233 
(6,18). However, in cats the density of capillaries in the subcutaneous tissue of the knee fold 234 
has not been studied. In humans, blood flow in adipose tissue has been shown to differ among 235 
various regions of the body (20). 236 
The sensors are expected to measure glucose concentrations without prolonged interruptions 237 
after the first calibration. The performance of sensors in the lateral chest wall, dorsal neck and 238 
knee fold with respect to uninterrupted function was similar; interruptions that lasted less than 239 
3 hours over a 48–hour period occurred in 85%, 70% and 70% of the sensors, respectively. Of 240 
course, uninterrupted glucose concentrations recordings do not imply that recordings are 241 
necessarily accurate. However, it is important to know which of the different sensor sites 242 
yielded fewer problems after the first calibration. All interruptions were caused by calibration 243 
errors. Calibration errors usually were preceded by large discrepancies between the PBGM 244 
measurement used for calibration and the CGMS readings (e.g. PBGM 15 mmol/l and CGMS 245 
5 mmol/l), and the CGMS values were always lower than the PBGM reference values. A 246 
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similar decrease in the ISIG before the occurrence of abnormal sensor function, which also 247 
led to calibration errors, has been documented in human diabetics (21). The ISIG identifies 248 
the small electric current produced by the electrochemical reaction between glucose in the 249 
interstitial fluid and glucose oxidase on the sensor electrode. The ISIG is subsequently 250 
converted to glucose concentration (mmol/l). Thus, the direct relationship between the 251 
glucose concentration in the interstitial fluid and the ISIG means that as the glucose 252 
concentration increases or decreases in the interstitial fluid, so does the ISIG. However a low 253 
ISIG can occur if the diffusion field nearby the sensor is disturbed. Other factors, like oxygen 254 
deficit, chemical interferences and enzyme inactivation can also impair the association 255 
between glucose concentration and sensor signal (22). Further investigations are necessary to 256 
verify which of the above factors disturbs glucose sensor function in diabetic cats. 257 
The sensor lost the proper placement in only five cats. This occurred in one sensor in the 258 
lateral chest wall, two sensors in the dorsal neck and two sensors in the knee fold, suggesting 259 
that the thoracic region is a more secure location for sensor placement. Hind limb movement 260 
resulting in detachment of the sensor from the skin may explain why loosening occurred more 261 
frequently in the knee fold region. Likewise, frequent and vigorous lateral and vertical 262 
movements of the head may gradually break the attachment between the sensor and the skin 263 
in the neck area. 264 
Similar to the results of our previous study (5), the glucose concentration measured by the 265 
sensors was generally lower than the reference value, regardless of sensor location. This 266 
discrepancy notwithstanding, error grid analysis revealed a satisfactory clinical accuracy, with 267 
96.1% of glucose values being in zone A and B. A small proportion of measurements from 268 
sensors in the lateral chest wall (0.8%) and knee fold (0.7%) were in zone E. In these cases, 269 
the CGMS yielded glucose values in the hypoglycaemic range, whereas the actual capillary 270 
glucose concentration measured with the PBGM was in the hyperglycaemic range, which 271 
would confuse treatment of hyperglycaemia with treatment of hypoglycaemia. The reason for 272 
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this underestimation of the glucose concentration is not clear, but may be due to insufficient 273 
sensor perfusion leading to drop in the ISIG. Sensors in the dorsal neck yielded no readings in 274 
zone E and thus none of those measurements would have confused treatment. Based on these 275 
results, sensors placed in the dorsal neck appear to be clinically more accurate and reliable. 276 
Furthermore, concordance between values generated by the PBGM and sensors in the dorsal 277 
neck was better than for the sensors in the other two locations, although the difference was 278 
minimal. Of note, differences between CGMS and PBGM measurements tended increase at 279 
higher glucose concentrations, especially for the lateral chest and knee sites. This findings is 280 
in agreement with previous observations in cats (5). Analytical accuracy is lower in the 281 
hyperglycaemic range, although the clinical relevance is minimal (5). 282 
There are some limitations to this study that need to be discussed. First, differences between 283 
the three sensor sites were not assessed with statistical methods in order to objectively verify 284 
whether one was superior to the others. Analysis was not performed because sample size was 285 
relatively small, in particular for knee and neck regions, and because for correct interpretation 286 
of the results sensors should have been placed at the three sensor sites simultaneously. For 287 
animal welfare reasons this was not considered acceptable by the Veterinary Office that 288 
supervised the study.. Second, interruptions of recording shorter than 3 hours were arbitrarily 289 
tolerated. Although in the authors experience interruptions shorted than 3 hours (over a period 290 
of 2 or more days) do not affect interpretation of the curves, if the cat has stable glucose 291 
levels and shows no signs of hypoglycaemia, no specific investigation has been performed to 292 
assess whether this is true in a clinical setting. Finally, it is worth mentioning that results of 293 
the CGMS were compared with those of the reference PBGM. Although the PBGM has been 294 
previously validated (7), small differences with the true gold standard (i.e., hexokinase 295 
method) may have, at least in part, biased the results of the present study.In summary sensor 296 
placement is feasible in any of the three sites used in this study and did not cause any adverse 297 
reactions in cats. Sensor detachment occurred least frequently in the lateral chest wall. This 298 
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preliminary study suggests that dorsal neck placement may be superior to lateral chest wall 299 
and lateral knee fold, however further investigation with a larger number of cases would be 300 
required to confirm this finding.  301 
 302 
Footnotes 303 
a
 Guardian REAL-Time
®
 continuous glucose monitoring system, Medtronic, 304 
Münchenbuchsee, Switzerland 305 
b
 Body Condition Score of Purina Pet Care Center 306 
c 
cyanolit
®
 universal classic, 3M Consumer Health Care, Rüschlikon, Switzerland  307 
d 
AlphaTRAK

 portable blood glucose meter, Abbott Animal Health, Maidenhead, England 308 
e 
Microlet Vaculance, Bayer 309 
 310 
Abbreviations: 311 
BGC   blood glucose curve 312 
CGMS  continuous glucose-monitoring systems 313 
PBGM   portable blood glucose meter 314 
ISIG  Input signal for glucose 315 
 316 
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Figure legends 371 
 372 
Fig. 1. Scatterplots of the differences between glucose concentrations obtained by use of the 373 
Guardian REAL-Time
®
 CGMS at different sensor sites ((A) lateral chest wall, (B) neck and 374 
(C) knee fold ) versus blood glucose concentration obtained with the reference PBGM 375 
AlphaTRAK
 
in cats. 376 
 377 
Fig. 2. Error grid analysis for the Guardian REAL-Time
®
 CGMS in cats. Results of the 378 
CGMS that fall in zone A deviate from the reference method value by no more than 20%, or 379 
the CGMS value and the reference method value are < 3.9 mmol/l. Results of the CGMS that 380 
fall in zone B deviate from the reference method value by > 20%, but reliance on results of 381 
the CGMS to make treatment decisions would not cause unacceptable errors in treatment. 382 
Values in zone C lead to unnecessary correction or overcorrection of glucose concentrations. 383 
Reliance on CGMS value in zone D would result in a failure to detect glucose concentrations 384 
outside the reference range. CGMS values in zone E would result in erroneous treatment with 385 
insulin. (A) The glucose sensors placed in the lateral chest wall yielded 94.3% in zones A or 386 
B, 4.9% in zone D and 0.8% in zone E. (B) Glucose sensors placed in the dorsal neck yielded 387 
96.7% of measurements in zones A or B and 3.3% in zone D. (C) Glucose sensors at the knee 388 
fold yielded 99.3% of measurements in zones A or B and 0.7% in zone E.  389 
